Embrace Hydrogel Embolic System (HES)
Instylla, Inc. · Decision date Feb 12, 2026
What did the FDA approve?
FDA records P250003/S004 as a supplement to PMA P250003, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Feb 12, 2026.
FDA approval order statement
approval for a new marketing material
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 12, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P250003/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Instylla, Inc.
- Product code
- QVG
- Decision code
- APPR
- Decision date
- Feb 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Embolization Agent, Vascular.
- Applicant
- Instylla, Inc.
- Product code
- QVG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250003 · Original PMA
Embrace(TM) Hydrogel Embolic System
P250003/S001 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S002 · Related supplement
Embrace Hydrogel Embolic System (HES)
P250003/S004 received
Application receipt date recorded by FDA.
P250003/S003 · Related supplement
Embrace Hydrogel Embolic System
P250003/S004 · FDA decision
Special (Immediate Track)
P250003/S006 · Related supplement
Embrace Hydrogel Embolic System (HES)
P250003/S005 · Related supplement
Embrace Hydrogel Embolic System (HES)
P250003/S009 · Related supplement
Embrace Hydrogel Embolic System
P250003/S010 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S008 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S011 · Related supplement
Embrace Hydrogel Embolic System
Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Instylla, Inc. | PMA approval | Aug 5, 2025 | FDA | |
Embrace(TM) Hydrogel Embolic SystemP250003/S001 | Instylla, Inc. | PMA supplement | Nov 25, 2025 | FDA |
Embrace Hydrogel Embolic System (HES)P250003/S002 | Instylla, Inc. | PMA supplement | Dec 17, 2025 | FDA |
Embrace Hydrogel Embolic SystemP250003/S003 | Instylla, Inc. | PMA supplement | Feb 4, 2026 | FDA |
Embrace Hydrogel Embolic System (HES)P250003/S006 | Instylla, Inc. | PMA supplement | Apr 1, 2026 | FDA |
Embrace Hydrogel Embolic System (HES)P250003/S005 | Instylla, Inc. | PMA supplement | Apr 2, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S009 | Instylla, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S010 | Instylla, Inc. | PMA supplement | Oct 21, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S008 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S011 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code QVG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Lava Liquid Embolic System (Lava LES)P220020/S008 | Sirtex Medical, Inc. | PMA supplement | Jul 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Instylla, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., North Bldg., Bedford, MA, 01730
Sources and methodology
- Original FDA record: P250003/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





